Biotherapeutic Drug Discovery Project Awards

About this scheme

Key information

Career level
Early career researcher
Established independent researcher
Clinician
Non-clinical researcher
Research area
Drug discovery
Pre-clinical research
Immunotherapy
Preliminary submission
Final submission
Committee review
Funding period
Typically 1 to 3 years*
Funding amount
Typically £100,000 per annum*
This funding scheme aims to increase the availability of biotherapeutic drugs for the management of cancer.

You should be:

  • A scientist, clinician or health care worker with a salaried position for the full duration of the award
  • Based at a UK university, medical school, hospital or research institution

You don’t need prior experience of working in drug discovery, but early interaction with a professional drug discovery partner will enhance your application.

We will also support collaborative projects between an academic partner and a commercial partner where appropriate. In some circumstances, non-UK based collaborators are accepted.

Scientific remit

This scheme funds projects at any stage of drug discovery, from target (pathway) identification and validation to early preclinical studies. Awards can support early stage translational research with a clear pathway towards further biotherapeutic development.

Examples of eligible studies include:

  • Validation of a novel target or pathway as a potential biotherapeutic drug target
  • The generation and pre-clinical testing of new biotherapeutic drug candidates
  • Re-positioning clinically validated biotherapeutic drugs in new oncology indications
  • Validation of novel combinations of biotherapeutic drugs or combinations of biotherapeutics with small molecule drugs (or other therapeutic modalities) in oncology indications
  • Application of novel technologies to improve the efficacy of biotherapeutic drugs

This scheme does not fund preclinical development studies required for the initiation of clinical studies, including bulk synthesis/manufacture to GMP or toxicology to GCP.

Eligible biotherapeutics include, but are not limited to:

  • Therapeutic antibodies
  • Cell based therapies
  • Viral therapies
  • Vaccines
  • Protein therapies
  • Gene therapies

Funding is provided for:

  • Typically 1-3 years
  • Typically £100,000 per year*
  • Salaries for postdoctoral researchers and technical staff
  • Running expenses
  • Equipment up to £15,000 if required for the project

If you require longer-term support where the aim is to answer an interrelated set of questions, you should consider applying for our Biotherapeutic Programme Award.

This scheme will not support the salary for the lead applicant. For a detailed breakdown of which costs are permitted, read our Costs Guidance (PDF).

*Proposals which fall outside of this timeline or funding amount may be considered with sufficient justification.

CRUK-MedImmune Alliance Laboratory

Successful applicants will also have the opportunity to access the CRUK-MedImmune Alliance Laboratory (CMAL). CMAL provides access to MedImmune’s proprietary human antibody phage display library and established antibody-engineering technologies, alongside the extensive expertise within the laboratory. When you first contact us to discuss opening your application, we will discuss with you whether CMAL could support your proposal. If you wish to access the CMAL, you should include this in your application.

If you are already a CRUK-funded scientist, you can apply directly to access the CMAL.

How to apply to this scheme

​Application process

Applications are considered twice a year and follow a three-stage process:

  1. Discussion: you must contact the research funding manager for an informal, confidential discussion about your proposed project. We will advise you on how to form suitable collaborations and ensure you are considering all necessary criteria within your proposal. Once the project is ready for a formal application we will open this on our electronic Grants Management System (eGMS).
  2. Outline application: you must submit a short outline application, which will be reviewed by the Biotherapeutic Expert Review Panel (BTERP) prior to being invited to submit a full application.
  3. Full application: if successful, you will be invited to submit a full application, and you will be asked to attend an interview with the BTERP

Final funding decisions will be made by the Drug Discovery Committee (DDC).

Timelines

Outline applications Full applications Interviews Funding decisions
13 December 2018 14 March 2019 29/30 April 2019 June 2019

Before you begin your application

Assessment criteria

Applications are assessed on their potential to develop a new preventative or therapeutic approach – the outputs of funded research should provide information that will significantly contribute to the development and eventual clinical testing of a medicine to deliver on an unmet medical need in oncology.

The Biotherapeutic Expert Review Panel will judge your proposal on:

  • Scientific excellence: all applications must have a strong scientific rationale to support the proposed research proposal.
  • Cancer-relevance: likely to advance how cancer is understood, prevented, diagnosed or treated.
  • Collective track record: the team should demonstrate their combined strengths and potential to produce outstanding results.
  • The strength of your research team and research environment.
  • The translational work plan, which should include:
    • Achievable milestones with go/no-go decision points
    • The specific deliverables of the project, for example assays, models or tools
    • A plan for further progression and the potential line of sight to the clinic at the end of the award

The Drug Discovery Committee will assess whether the application aligns with our Research Strategy.

Collaboration

When you first contact us to discuss opening your application, we will discuss with you whether suitable collaborations are in place to support the project.

Working with a professional drug discovery partner (academic or commercial) with experience of developing drug discovery proposals and project plans, will enhance your application for example by:

  • Aiding you in defining specific milestones for the project, with associated go/ no-go decisions points
  • Providing access to facilities and expertise (e.g. assay development, models, tools, phage display libraries)
  • Participating in regular meetings to aid in project management and guiding the future direction and clinical translation of the project.

Applications are assessed by the Biotherapeutics Expert Review Panel (BTERP). Final funding decisions are made by the Drug Discovery Committee (DDC).

Cancer Research UK contact details

Dr Rupal Mistry

Research Funding Manager

drugdiscovery.committee@cancer.org.uk

Tel: +44 (0) 203 469 8732

Our drug discovery infrastructure

To support our investigator-led drug discovery research we have made extensive investment in infrastructure for biotherapeutic and small molecule drug discovery.

Where next for cancer immunotherapy?

Where next for cancer immunotherapy?

We're driving discovery research in immuno-oncology which is leading to novel and exciting immunotherapeutic possibilities.